Aliqopa

Chemical Namecopanlisib
Dosage FormInjection (intravenous; 60 mg/vial)
Drug ClassKinase inhibitors
SystemBlood
CompanyBayer HealthCare Pharmaceuticals Inc.
Approval Year2017

Indication

  • Aliqopa is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Aliqopa (copanlisib) Prescribing Information.2020Bayer Healthcare